News | Prostate Cancer | May 02, 2024

Extending beyond brain tumors, empowering patients with treatment options in prostate cancer and other malignancies

Extending beyond brain tumors, empowering patients with treatment options in prostate cancer and other malignancies

Getty Images

May 2, 2024 — GT Medical Technologies, Inc. (GT MedTech), a medical device company with the mission of improving the lives of patients with brain tumors, today announced it has entered into a strategic distribution partnership with Theragenics Corporation (Theragenics), a global leader in minimally invasive brachytherapy. The partnership aims to expand physician access to Cesium-131 seeds, offering greater flexibility to support their brachytherapy procedural needs.

Through the partnership, Theragenics will become the exclusive distributor of Cesium-131 brachytherapy seeds and carriers used for a variety of non-brain cancer related treatments including prostate cancer. GT MedTech, the sole manufacturer of Cesium-131, will continue to focus on expanding adoption of the company’s FDA-cleared revolutionary GammaTile therapy for the treatment of operable brain tumors in the U.S.

Cesium-131 is a common isotope used with Low Dose Rate [LDR] brachytherapy, a radiation treatment where tiny radioactive seeds are implanted directly into or adjacent to a tumor. This approach delivers a high dose of radiation to cancer cells while minimizing damage to surrounding healthy tissues.

“We are very pleased to align with Theragenics, a global brachytherapy leader, to propel the field of cancer care forward.” said Per Langoe, CEO of GT Medical Technologies. “This partnership ensures continued access to Cesium-131 for clinicians and patients, addressing critical healthcare needs.”

Michael Krachon, President of Theragenics Interventional, added, “This partnership reinforces Theragenics’ unwavering commitment to brachytherapy. With the addition of Cesium-131 to our portfolio, we can more comprehensively support the clinical needs of the brachytherapy community and further expand our efforts to raise awareness of brachytherapy as a viable treatment option for men battling prostate cancer.”

As the exclusive manufacturer of Cesium-131, GT MedTech is dedicated to expanding its utilization to advance cancer care. Concurrently, GT MedTech is focused on driving the evidence-based adoption of GammaTile, aiming to establish a new standard of care for operable brain tumors.*

*See Product IFU for detailed information. 

For more information:

Related Content

News | Radiation Therapy

June 19, 2024 — RaySearch Laboratories AB announced a milestone in radiotherapy technology where RaySearch’s RayStation ...

Time June 19, 2024
News | Artificial Intelligence

June 17, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care ...

Time June 17, 2024
News | Proton Therapy

June 14, 2024 — Atlantic Health System, an integrated health care system setting standards for quality health care in ...

Time June 14, 2024
News | PET Imaging

June 14, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 14, 2024

June 11, 2024 — A newly developed radiotracer can generate high quality and readily interpretable images of cardiac ...

Time June 11, 2024
News | FDA

June 10, 2024 — Siemens Healthineers announces the Food and Drug Administration clearance of the Biograph Trinion, a ...

Time June 10, 2024
News | Breast Imaging

June 7, 2024 — Scholars and studies funded by Susan G. Komen(R), the world’s leading breast cancer organization ...

Time June 07, 2024
News | Radiopharmaceuticals and Tracers

June 7, 2024 — Shine Technologies, LLC, a pioneer in next-generation fusion-based technology, today announced a new ...

Time June 07, 2024
News | Information Technology

June 4, 2024 — International medical imaging IT and cybersecurity company Sectra has launched a new diagnostic IT module ...

Time June 04, 2024
Feature | Radiology Business | By Melinda Taschetta-Millane

As we flip the page to a new month on our calendars, here is a look at the Top 10 pieces of content viewers were reading ...

Time June 04, 2024
Subscribe Now